Navigation Links
Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
Date:4/2/2009

-- European Commission grants marketing authorization for Intercell's IXIARO, the first licensed vaccine against Japanese Encephalitis for travelers and military personnel in Europe

-- This final decision follows the positive opinion from European Committee for Human Medicinal Products (CHMP) in December 2008

VIENNA, April 2 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that its new vaccine to prevent Japanese Encephalitis, IXIARO(R), has been approved by the European Commission. The approval by the European Union, the first for a vaccine to prevent the disease, provides formal market authorization in all 27 member states as well as Norway and Iceland.

"The European approval of IXIARO marks a crucial milestone in Intercell's evolution as one of the leading independent vaccine development companies with a vaccine marketed," said Intercell's Chief Executive Officer Gerd Zettlmeissl. "For the first time, both civilians and members of the military across Europe will have access to a safe and effective vaccine against this devastating and endemic disease found throughout Asia, which kills as many as one in three of the people it strikes."

This decision follows the positive opinion from European Committee for Human Medicinal Products (CHMP) in December 2008. Novartis AG holds marketing and distribution rights for IXIARO, in the United States, Europe, Japan, Korea and certain other markets in Asia and Latin America.

A final assessment by the European COMP (Committee for Orphan Medicinal Products) focused on updated information indicating that the expected potential European vaccine market for IXIARO is significantly higher than initially evaluated, and, therefore, the vaccine will not have an orphan drug designation.

Intercell's product is a purified, inactivated vaccine for active immunization against infections with Japanese Encephalitis virus. The
'/>"/>

SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
2. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
3. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
4. Iomai Stockholders Approve Merger With Intercell Subsidiary
5. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
6. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
7. China Biologic Products Announces Strong 2008 Results
8. Senetek PLC Announces New Investor Communication Hotline
9. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
10. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
11. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , ... July 31, 2015 , ... ... competitive market analysis and premium industry insights on the global resorcinol industry. The ... a collective study of vivid market scenarios and analysis of primary and secondary ...
(Date:7/30/2015)... July 30, 2015 AACC welcomed thousands ... 2015 AACC Annual Meeting & Clinical Lab Expo ... 26–30. The meeting showcased revolutionary advancements in clinical ... of healthcare providers to diagnose patients quickly and ... treatment. As of Wednesday, July ...
(Date:7/30/2015)... 2015 According to a new ... Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract ... Trial), by End Users - Global Forecast to 2020", ... reach USD 2,107.99 million by 2020 from USD 1,034.93 ... Browse more than 75 ...
(Date:7/30/2015)... customers across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ... and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... Group,Inc. (Nasdaq: NYER ) reported results for the fiscal ... June 30, 2008 increased $6.6,million or 10.2% to $71.2 million ... loss for the fiscal year ended June 30, 2008 was,$403,520 ... of $86,446 or $.02,per share for the previous fiscal year., ...
... ACEL ) today reported its financial results for ... The company recorded a net loss of approximately ... for the fourth fiscal quarter ended,July 31, compared to ... per,basic and diluted common share, for the fourth quarter ...
... HARBIN, China, Oct. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky ... Company") (NASDAQ: CSKI ), a,leading fully integrated ... of China ("PRC"), announced today that it,started production ... a,pharmaceutical company that it acquired, on October 14, ...
Cached Biology Technology:Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008 2Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008 3Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 2Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 3Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 4Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results 5China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance 2China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance 3
(Date:7/7/2015)... Calif. , July 7, 2015  Based ... market, Frost & Sullivan recognizes Credence ID, LLC ... Entrepreneurial Company of the Year Award. Credence ... to aid in its mission of offering enrollment ... populations globally. As Credence ID was formed by ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
(Date:7/2/2015)... GOTHENBURG, Sweden , July 2, 2015 ... fingerprint sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor ... is one of FPC,s distributors in Asia ... Q4 2015. The sensors will be used by smartphone manufacturers ... 268 MSEK is included in the communicated revenue guidance of ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... long been considered a major risk factor for cardiovascular ... risk, but the mechanisms of how arteries stave off ... the Perelman School of Medicine, University of Pennsylvania, Wistar ... that the protein apolipoprotein E (apoE) plays a major ...
... the Nowgen Schools Genomics Programme website launches with a range ... genetics in schools and colleges. , Developments in genetics research ... at a cost of $3 billion to sequencing a genome ... genetics in classroom education have remained relatively static. The pace ...
... Research led by Chu Chen, PhD, Associate Professor of Neuroscience ... enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target ... online November 1, 2012 in the Online Now section of ... that inactivation of MAGL, best known for its role in ...
Cached Biology News:Softening arteries, protecting the heart 2Softening arteries, protecting the heart 3Bridging the gap between genomics and education 2LSUHSC research identifies new therapeutic target for Alzheimer's disease 2
... silencing experiments often call for critical, ... Transfection Agent refines siRNA transfection protocols ... lipid-based formulation can be used to ... are subcultured without increased cytotoxicity. ...
... The CHEMICON® CaspaTag™ Pan-Caspase In Situ ... detection of active caspases in cells undergoing ... only. Not for use in diagnostic or ... Assay Kits use a novel approach to ...
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
... Cell and Tissue Staining Kits are intended ... range of histological and cytological specimens. These ... antibodies manufactured by either R&D Systems or ... on the formation of the Avidin-Biotin Complex ...
Biology Products: